*仅供医学专业人士阅读参考我们知道，在一些血液系统恶性肿瘤中，HDAC抑制剂（HDACi）表现出了不错的疗效，但在实体瘤方面，HDACi的疗效确实有点不尽如人意，这与其耐药问题有关。既往有研究显示，肿瘤微环境的改变可能是导致HDACi耐药的一个因素， ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in ...

ATC免疫刺激的概念超越了CD47，如今研究人员已经开发了新型策略，其能靶向作用其它肿瘤特异性受体来制造ADCs，从而促使机体针对多种难以治疗的癌症。研究人员的目标是在未来三至五年内为临床试验做好首批准备。综上，本文研究结果表明，设计ATCs来促进机 ...

As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data ...

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) have been given an average rating of “Moderate Buy” by ...

ALX Oncology Holdings Inc.’s ALXO share price has dipped by 19.08%, which has investors questioning if this is right time to ...

Targeting metabolic dependencies, such as glucose or lipid metabolism, is a key strategy for anti-cancer therapies. Nguyen et al. developed a new approach, adipose manipulation transplantation ...

“In 2024, we delivered strong progress and continued momentum for our clinical development program evaluating evorpacept as a ...

ALX Oncology (ALXO) will highlight progress across its clinical pipeline, including continued advancement of investigational CD47-blocker ...

ALX Oncology (NASDAQ:ALXO – Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.72) ...

We work right across the cancer research pathway with strengths ranging from cell biology to healthcare research. We aim to nurture the thought leaders of today and tomorrow through the provision of ...